+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

Solid Tumors Target Proteins Market - Global Forecast 2026-2032 - Product Thumbnail Image

Solid Tumors Target Proteins Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 181 Pages
  • Global
From
From
From
From
From
From
From
From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
From
From
From
From
From
From
Checkpoint Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 180 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2026 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2026

  • Report
  • January 2026
  • 250 Pages
  • Global
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more